Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    10600329 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Phase 2/3 Study of IGSC, 20% in PIDD
Condition: Primary Immunodeficiency Diseases(PIDD)
Interventions: Biological: Immune Globulin Intravenous (Human), 10% Solution;   Drug: Immune Globulin Subcutaneous (Human), 20% Solution

Indicates status has not been verified in more than two years